KRAS and cancer: On day 20 post THZ1 treatment, the relative proliferation rates of cancer cells T/Cs (%) were significantly lower in CAPAN2 (KRAS‐G12V) cells than in SW1990 (KRAS‐G12D) cells with both 5 mg/kg (50.0% vs.